[go: up one dir, main page]

LUC00296I2 - - Google Patents

Info

Publication number
LUC00296I2
LUC00296I2 LU00296C LUC00296C LUC00296I2 LU C00296 I2 LUC00296 I2 LU C00296I2 LU 00296 C LU00296 C LU 00296C LU C00296 C LUC00296 C LU C00296C LU C00296 I2 LUC00296 I2 LU C00296I2
Authority
LU
Luxembourg
Application number
LU00296C
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55315708&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LUC00296(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of LUC00296I2 publication Critical patent/LUC00296I2/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/645—Secretins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
LU00296C 2015-01-09 2023-02-03 LUC00296I2 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562101488P 2015-01-09 2015-01-09

Publications (1)

Publication Number Publication Date
LUC00296I2 true LUC00296I2 (fr) 2025-09-22

Family

ID=55315708

Family Applications (1)

Application Number Title Priority Date Filing Date
LU00296C LUC00296I2 (fr) 2015-01-09 2023-02-03

Country Status (46)

Country Link
US (1) US9474780B2 (fr)
EP (2) EP3597662A1 (fr)
JP (3) JP6219534B2 (fr)
KR (5) KR20210145311A (fr)
CN (2) CN107207576B (fr)
AR (2) AR103242A1 (fr)
AU (1) AU2016205435B2 (fr)
CA (1) CA2973352C (fr)
CL (1) CL2017001760A1 (fr)
CO (1) CO2017006737A2 (fr)
CR (1) CR20170310A (fr)
CY (2) CY1122028T1 (fr)
DK (1) DK3242887T3 (fr)
DO (1) DOP2017000153A (fr)
EA (3) EA035055B1 (fr)
EC (1) ECSP17043648A (fr)
ES (1) ES2747928T3 (fr)
FI (1) FIC20230005I1 (fr)
FR (1) FR23C1006I2 (fr)
HR (1) HRP20191614T1 (fr)
HU (2) HUE045860T2 (fr)
IL (4) IL281545B2 (fr)
JO (2) JOP20200119A1 (fr)
LT (2) LT3242887T (fr)
LU (1) LUC00296I2 (fr)
MA (2) MA50422A (fr)
MD (1) MD3242887T2 (fr)
ME (1) ME03494B (fr)
MX (2) MX382753B (fr)
MY (1) MY193616A (fr)
NL (1) NL301217I2 (fr)
NO (1) NO2023005I1 (fr)
NZ (3) NZ771547A (fr)
PE (1) PE20170954A1 (fr)
PH (1) PH12017501252B1 (fr)
PL (1) PL3242887T3 (fr)
PT (1) PT3242887T (fr)
RS (1) RS59146B1 (fr)
SG (1) SG11201705603YA (fr)
SI (1) SI3242887T1 (fr)
SV (1) SV2017005453A (fr)
TN (1) TN2017000198A1 (fr)
TW (1) TWI582109B (fr)
UA (1) UA118239C2 (fr)
WO (1) WO2016111971A1 (fr)
ZA (1) ZA201703930B (fr)

Families Citing this family (105)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106456589B (zh) 2013-12-18 2020-07-07 斯克利普斯研究所 修饰的治疗剂、订合的肽脂质缀合物及其组合物
TWI622596B (zh) 2015-10-26 2018-05-01 美國禮來大藥廠 升糖素受體促效劑
US11285180B2 (en) 2016-12-06 2022-03-29 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods of enhancing the potency of incretin-based drugs in subjects in need thereof
JOP20180028A1 (ar) 2017-03-31 2019-01-30 Takeda Pharmaceuticals Co مركب ببتيد
EP3624828B1 (fr) * 2017-05-18 2024-08-07 Merck Sharp & Dohme LLC Formulation pharmaceutique comprenant des conjugués d'incrétine-insuline
MA46990B1 (fr) 2017-08-24 2024-03-29 Novo Nordisk As Compositions glp-1 et ses utilisations
TWI744579B (zh) * 2017-12-21 2021-11-01 美商美國禮來大藥廠 腸促胰島素(incretin)類似物及其用途
TWI767095B (zh) * 2017-12-21 2022-06-11 美商美國禮來大藥廠 腸促胰島素(incretin)類似物及其用途
WO2019140030A1 (fr) * 2018-01-12 2019-07-18 Eli Lilly And Company Polythérapie
MX2020007598A (es) 2018-02-02 2020-09-03 Novo Nordisk As Composiciones solidas que comprenden un agonista del peptido similar al glucagon tipo 1 (glp-1), una sal del acido n-(8-(2-hidroxibenzoil)amino)caprilico y un lubricante.
CN112135832A (zh) 2018-03-22 2020-12-25 维京治疗公司 化合物的晶型和制备化合物的晶型的方法
TWI707865B (zh) * 2018-05-04 2020-10-21 丹麥商諾佛 儂迪克股份有限公司 Gip衍生物及其用途
TWI705820B (zh) * 2018-06-22 2020-10-01 美商美國禮來大藥廠 Gip/glp1促效劑組合物
MY197569A (en) * 2018-07-23 2023-06-25 Lilly Co Eli Gip/glp1 co-agonist compounds
WO2020023382A1 (fr) * 2018-07-23 2020-01-30 Eli Lilly And Company Procédés d'utilisation d'un co-agoniste de gip/glp1 pour une thérapie
EP4450127A3 (fr) * 2018-07-23 2025-01-01 Eli Lilly and Company Procédé d'utilisation d'un co-agoniste de gip/glp1 contre le diabète
WO2020023702A1 (fr) 2018-07-25 2020-01-30 AskGene Pharma, Inc. Nouveaux promédicaments d'il-21 et leurs procédés d'utilisation
JP6564539B1 (ja) 2018-09-14 2019-08-21 長瀬産業株式会社 スルホン酸化合物によるペプチド精製方法
EP3856339A1 (fr) 2018-09-24 2021-08-04 Takeda Pharmaceutical Company Limited Composés peptidiques agonistes du récepteur gip et leurs utilisations
JP2022510691A (ja) 2018-12-05 2022-01-27 バイキング・セラピューティクス・インコーポレイテッド 線維症及び炎症の処置のための組成物
TWI799680B (zh) * 2019-01-29 2023-04-21 美商美國禮來大藥廠 製備gip/glp1雙重促效劑之方法
GB201908424D0 (en) 2019-06-12 2019-07-24 Imp College Innovations Ltd Novel compounds
WO2020252264A1 (fr) 2019-06-12 2020-12-17 AskGene Pharma, Inc. Nouveaux promédicaments d'il-15 et leurs procédés d'utilisation
AR119471A1 (es) * 2019-08-01 2021-12-22 Lilly Co Eli Compuestos agonistas de gipr
PE20221049A1 (es) 2019-08-19 2022-06-30 Lilly Co Eli Metodos para preparar analogos de incretina
WO2021066600A1 (fr) 2019-10-04 2021-04-08 한미약품 주식회사 Glucagon, composition comprenant un agoniste double du récepteur de glp-1 et du récepteur de gip et utilisation thérapeutique associée
CN110684082B (zh) * 2019-10-08 2021-12-10 江苏诺泰澳赛诺生物制药股份有限公司 Gip和glp-1双激动多肽化合物及药学上可接受的盐与用途
AR120714A1 (es) * 2019-12-18 2022-03-09 Lilly Co Eli Análogos de incretina y sus usos
AR121093A1 (es) 2020-01-23 2022-04-20 Lilly Co Eli Compuestos coagonistas de gip / glp1
TW202140058A (zh) * 2020-01-30 2021-11-01 美商美國禮來大藥廠 提派肽（ｔｉｒｚｅｐａｔｉｄｅ）之治療用途
CN111253475B (zh) * 2020-02-18 2021-03-09 江苏诺泰澳赛诺生物制药股份有限公司 Glp-1激动多肽化合物及其盐与合成方法及用途
AU2021229621B2 (en) 2020-03-06 2023-08-31 Sanofi Peptides as selective GIP receptor agonists
CN113493503B (zh) * 2020-04-08 2022-08-05 浙江道尔生物科技有限公司 一种肠促胰岛素类似物及其制备方法和用途
TW202216746A (zh) * 2020-06-22 2022-05-01 印度商太陽製藥工業有限公司 長效型ｇｌｐ－１／ｇｉｐ雙重促效劑
CN116113429A (zh) * 2020-07-06 2023-05-12 鸿绪生物医药科技（北京）有限公司 新型多肽及其治疗用途
CA3184723A1 (fr) 2020-07-22 2022-01-27 Patrick J. KNERR Co-agonistes de recepteurs de glp-1 et de gip
TWI801942B (zh) 2020-07-22 2023-05-11 丹麥商諾佛 儂迪克股份有限公司 適用於口服的glp-1及gip受體共促效劑
WO2022068920A1 (fr) * 2020-09-30 2022-04-07 Beijing Ql Biopharmaceutical Co., Ltd. Conjugués polypeptidiques et leurs procédés d'utilisation
WO2022080986A1 (fr) * 2020-10-16 2022-04-21 한미약품 주식회사 Agoniste double de glp-1/gip, conjugué à action prolongée de celui-ci, et composition pharmaceutique le comprenant
US20240020543A1 (en) * 2020-10-17 2024-01-18 Sun Pharmaceutical Industries Limited Glp-1/gip dual agonists
EP4257597A4 (fr) * 2020-12-02 2025-04-02 Dongbao Purple Star (Hangzhou) Biopharmaceutical Co., Ltd. Composés polypeptidiques modifiés par lactame
KR102691149B1 (ko) 2021-01-20 2024-08-05 바이킹 테라퓨틱스 인코포레이티드 대사 및 간 질환 치료를 위한 조성물 및 방법
CN116867505A (zh) 2021-02-17 2023-10-10 伊莱利利公司 替西帕肽治疗方法
CA3208873A1 (fr) * 2021-02-17 2022-08-25 Mathijs Christiaan Michael BUNCK Procedes therapeutiques agonistes doubles gip/glp1
US12215133B2 (en) 2021-03-25 2025-02-04 Brightgene Bio-Medical Technology Co., Ltd. GIP and GLP-1 dual receptor agonist, pharmaceutical composition, and use
BR112023019389A2 (pt) 2021-03-25 2023-11-28 Brightgene Bio Medical Tech Co Ltd Compostos, agonista de receptor duplo de gip e glp-1, composição farmacêutica compreendendo os mesmos, uso dos mesmos e método para prevenir e/ou tratar doenças associadas a distúrbios metabólicos
US20240226017A1 (en) 2021-05-07 2024-07-11 Eli Lilly And Company Erodible tablet
GEAP202416419A (en) 2021-05-13 2024-03-25 Carmot Therapeutics Inc Modulators of g-protein coupled receptors
CN118307645A (zh) * 2021-05-28 2024-07-09 广东众生睿创生物科技有限公司 多肽的制备及其应用
CA3222051A1 (fr) * 2021-06-01 2022-12-08 Nanjing Zhihe Medicine Technology Co., Ltd. Derive polypeptidique ayant un effet d'activation a double cible de glp-1r et de gipr, procede de preparation associe et son utilisation
MX2023014771A (es) 2021-06-09 2024-03-19 Scripps Research Inst Conjugados peptidicos duales gip/glp-1 de accion prolongada y metodos de uso.
TW202302624A (zh) * 2021-06-18 2023-01-16 大陸商廣東眾生睿創生物科技有限公司 含內醯胺橋的多肽化合物
CN118159552A (zh) 2021-09-06 2024-06-07 赛诺菲 作为强效的且选择性的gip受体激动剂的新肽
MX2024003236A (es) 2021-09-15 2024-06-19 Viking Therapeutics Inc Composiciones y metodos para el tratamiento de trastornos metabolicos y hepaticos.
EP4180060A1 (fr) 2021-11-15 2023-05-17 Adocia Compositions solides comportant un peptide ou une protéine et un acide aminé acylé
EP4299057A1 (fr) 2022-06-30 2024-01-03 Adocia Compositions solides comportant un peptide ou une protéine et un acide aminé acylé
WO2023084118A1 (fr) 2021-11-15 2023-05-19 Adocia Compositions solides comprenant un peptide ou une protéine et un acide aminé acylé
WO2023089594A1 (fr) 2021-11-22 2023-05-25 Sun Pharmaceutical Industries Limited Procédé de préparation de tirzépatide ou de sel pharmaceutiquement acceptable de celui-ci
TW202330584A (zh) 2022-01-20 2023-08-01 丹麥商諾佛 儂迪克股份有限公司 前藥及其用途
JP2025512980A (ja) * 2022-04-07 2025-04-22 広東衆生睿創生物科技有限公司 糖尿病、肥満症およびその関連疾患を治療および／または予防するための医薬品の調製における、ポリペプチドの医薬的使用
CN116947978A (zh) * 2022-04-19 2023-10-27 北京惠之衡生物科技有限公司 一种glp-1和gip受体共激动多肽衍生物及其盐和制剂
PE20250835A1 (es) 2022-06-30 2025-03-21 Lilly Co Eli Composiciones y uso de la tirzepatida
EP4299052A1 (fr) 2022-06-30 2024-01-03 Adocia Compositions solides comportant un peptide ou une protéine et un agent améliorant la perméation
EP4299071A1 (fr) 2022-07-01 2024-01-03 Adocia Compositions comprenant un peptide ou une protéine et un acide aminé acylé
KR20250037523A (ko) * 2022-07-13 2025-03-17 항저우 종메이화동 파마슈티칼 컴퍼니 리미티드 Glp-1/gip 이중 효능제, 이의 제조 방법 및 이의 용도
AU2023311214A1 (en) * 2022-07-20 2025-02-27 Viking Therapeutics, Inc. Pharmaceutical formulations and methods for the treatment of metabolic and liver disorders
JP2025530743A (ja) 2022-08-29 2025-09-17 イーライ リリー アンド カンパニー 経口投与のための組成物
EP4587462A1 (fr) * 2022-09-15 2025-07-23 Eli Lilly and Company Composés agonistes doubles de gip et de glp-1
TW202412835A (zh) * 2022-09-23 2024-04-01 大陸商博瑞生物醫藥(蘇州)股份有限公司 一種glp-1和gip雙受體激動劑藥物組合物及其用途
KR20250096895A (ko) 2022-10-05 2025-06-27 일라이 릴리 앤드 캄파니 인크레틴 합성을 위한 펩티드
WO2024086601A2 (fr) * 2022-10-19 2024-04-25 Eli Lilly And Company Compositions d'agonistes de gip/glp préservées
CN117756913B (zh) * 2022-11-07 2025-05-09 内蒙古博睿精创科技有限公司 一种新型长效多肽化合物、组合物及其应用
AU2023385357A1 (en) 2022-11-21 2025-06-05 Eli Lilly And Company Process for preparing a gip/glp1 dual agonist
JP2025539630A (ja) 2022-12-16 2025-12-05 ペプトロン インコーポレイテッド Ｇｌｐ－１受容体アゴニストまたはその薬学的に許容可能な塩を含む徐放性微粒球およびその用途
CN120435487A (zh) 2022-12-29 2025-08-05 伊莱利利公司 制备替尔泊肽的工艺和中间体
KR20250141711A (ko) 2022-12-30 2025-09-29 알지파마 에이에스 경구 투여되는 폴리펩타이드 치료제의 전신 생체이용률을 증가시키는 조성물 및 방법
IL322205A (en) 2023-01-31 2025-09-01 Lilly Co Eli GIP/GLP1/GCG trireceptor agonists and their uses
WO2024165571A2 (fr) 2023-02-06 2024-08-15 E-Therapeutics Plc Inhibiteurs d'expression et/ou de fonction
AR132137A1 (es) * 2023-03-15 2025-05-28 Viking Therapeutics Inc Composiciones farmacéuticas y métodos para el tratamiento de trastornos metabólicos y hepáticos
CN118684758A (zh) * 2023-03-23 2024-09-24 上海民为生物技术有限公司 肠促胰岛素类似物及其应用
CN121001735A (zh) 2023-03-31 2025-11-21 伊莱利利公司 用于治疗t2d的替尔泊肽
CN121002051A (zh) * 2023-04-11 2025-11-21 上海多米瑞生物技术有限公司 肠促胰素类似物及其制备方法和应用
WO2024243243A1 (fr) * 2023-05-21 2024-11-28 Carmot Therapeutics Inc. Traitement d'adultes en surpoids ou obèses avec ou sans comorbidités liées au poids
CN116832141B (zh) * 2023-06-06 2024-02-09 诺博泰科(成都)生物科技有限公司 一种用于治疗糖尿病的glp-1、gip和gcg受体三激动多肽化合物
AU2024284396A1 (en) 2023-06-09 2026-01-08 Sun Pharmaceutical Industries Limited Glp-1/gip dual, glp-1/gcg dual and glp-1/gip/gcg triple receptor agonists
KR20240176455A (ko) 2023-06-15 2024-12-24 노보 노르디스크 에이/에스 시클로덱스트린을 포함하는 약학적 제형
AU2024306538A1 (en) 2023-06-30 2025-12-04 Zealand Pharma A/S Combination therapy
CN116693652B (zh) * 2023-08-02 2024-01-05 北京惠之衡生物科技有限公司 一种glp-1/gip受体双重激动剂衍生物及其制备方法和应用
WO2025069009A1 (fr) 2023-09-29 2025-04-03 Graviton Bioscience Bv Inhibiteurs de rock2 dans le traitement de l'obésité
CN117646017A (zh) * 2023-11-02 2024-03-05 中国人民解放军海军军医大学 Gip/glp-1双激动剂多肽编码基因、及其重组乳酸菌和应用
WO2025106773A1 (fr) 2023-11-17 2025-05-22 Apnimed, Inc. (Delaware) Méthodes et compositions pour le traitement de l'apnée du sommeil avec une combinaison d'un agoniste de glp-1 et d'un second agent actif
WO2025114501A1 (fr) 2023-11-30 2025-06-05 Novo Nordisk A/S Tri-agonistes des récepteurs glp-1, gip et amyline
WO2025125576A2 (fr) 2023-12-15 2025-06-19 E-Therapeutics Plc Inhibiteurs d'expression et/ou de fonction
CN120173084A (zh) * 2023-12-20 2025-06-20 深圳翰宇药业股份有限公司 一种替尔泊肽的合成方法
WO2025133348A1 (fr) 2023-12-22 2025-06-26 E-Therapeutics Plc Inhibiteurs d'expression et/ou de fonction
WO2025149039A1 (fr) * 2024-01-12 2025-07-17 杭州中美华东制药有限公司 Composition pharmaceutique d'agoniste double de glp-1/gip à action prolongée
WO2025163674A1 (fr) * 2024-01-30 2025-08-07 Msn Laboratories Private Limited, R&D Center Procédé de préparation du tirzépatide
WO2025185605A1 (fr) * 2024-03-05 2025-09-12 Beijing Ql Biopharmaceutical Co., Ltd. Conjugués polypeptidiques et procédés d'utilisation
WO2025191149A1 (fr) 2024-03-15 2025-09-18 Krka, D.D., Novo Mesto Composition pharmaceutique comprenant un agoniste du récepteur glp-1 et gip double
WO2025196502A1 (fr) 2024-03-20 2025-09-25 North Carolina Agricultural & Technical State University Inhibiteurs de choline kinase utilisés en tant que traitement thérapeutique contre l'obésité
US20250352622A1 (en) 2024-05-15 2025-11-20 Rose Pharma Inc. Glp-1 formulations and their uses
CN118440155B (zh) * 2024-07-11 2024-11-22 中国药科大学 一种双激动多肽化合物及其医药用途
US12434008B1 (en) 2025-02-26 2025-10-07 Genzyme Corporation Lock ring for a medicament delivery device
US12465697B1 (en) 2025-02-26 2025-11-11 Genzyme Corporation Medicament delivery device
US12420017B1 (en) 2025-02-26 2025-09-23 Genzyme Corporation Damping device for a medicament delivery device

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050272652A1 (en) * 1999-03-29 2005-12-08 Gault Victor A Peptide analogues of GIP for treatment of diabetes, insulin resistance and obesity
US20080171695A1 (en) 2005-02-02 2008-07-17 Novo Nordisk A/S Insulin Derivatives
US20100317057A1 (en) 2007-12-28 2010-12-16 Novo Nordisk A/S Semi-recombinant preparation of glp-1 analogues
CN102170895A (zh) * 2008-08-07 2011-08-31 益普生制药股份有限公司 葡萄糖依赖性促胰岛素多肽类似物
JP5591243B2 (ja) 2008-09-12 2014-09-17 ノボ・ノルデイスク・エー／エス ペプチド又はタンパク質のアシル化の方法
CN101367873B (zh) * 2008-10-08 2011-05-04 南开大学 一种改构的胰高血糖素样肽-1的类似物和修饰物及其应用
PE20120332A1 (es) 2008-12-19 2012-04-14 Univ Indiana Res & Tech Corp Profarmacos de peptido de la superfamilia de glucagon basado en amida
GB0917072D0 (en) * 2009-09-29 2009-11-11 Univ Ulster Peptide analogues of glucagon for diabetes therapy
MX2012008603A (es) 2010-01-27 2013-01-25 Univ Indiana Res & Tech Corp Conjugados de antagonista de glucagon-agonista de gip y composiciones para el tratamiento de desordenes metabolicos y obesidad.
AR080592A1 (es) * 2010-03-26 2012-04-18 Lilly Co Eli Peptido con actividad para el gip-r y glp-1-r, formulacion famaceutica que lo comprende, su uso para preparar un medicamento util para el tratamiento de diabetes mellitus y para inducir la perdida de peso
KR101091041B1 (ko) * 2010-07-29 2011-12-09 고려대학교 산학협력단 새로운 재조합 글루코스 의존성 인슐린분비 펩타이드(ｒｃＧＩＰ) 작용제 및 그 용도
CN103458920B (zh) 2010-12-22 2016-07-06 印第安那大学科技研究公司 表现出gip受体活性的胰高血糖素类似物
NZ611878A (en) * 2010-12-22 2015-02-27 Marcadia Biotech Inc Methods for treating metabolic disorders and obesity with gip and glp-1 receptor-active glucagon-based peptides
US9790262B2 (en) 2011-04-05 2017-10-17 Longevity Biotech, Inc. Compositions comprising glucagon analogs and methods of making and using the same
EP2718317B1 (fr) 2011-06-10 2018-11-14 Beijing Hanmi Pharmaceutical Co., Ltd. Analogues de polypeptides insulinotropes dépendants du glucose, compositions pharmaceutiques et son utilisation
WO2012171994A1 (fr) 2011-06-15 2012-12-20 Novo Nordisk A/S Insulines à substitutions multiples
EP2758426B1 (fr) 2011-09-23 2019-08-07 Novo Nordisk A/S Nouveaux analogues de glucagon
BR112014015681A2 (pt) * 2011-12-23 2019-09-24 Boehringer Ingelheim Int análogos de glucagon
EA028665B1 (ru) * 2012-05-03 2017-12-29 Зилэнд Фарма А/С Соединения - двойные агонисты gip-glp-1 и способы
CN104583232B (zh) * 2012-06-21 2018-04-13 印第安纳大学研究及科技有限公司 展现gip受体活性的胰高血糖素类似物
CN104955472A (zh) 2012-10-17 2015-09-30 诺和诺德保健股份有限公司 用于生长激素递送的脂肪酸酰化的氨基酸
SI2934568T1 (en) 2012-12-21 2018-03-30 Sanofi Dual GLP1 / GIP or trigonal agonists GLP1 / GIP / glucagon
UA118558C2 (uk) * 2013-05-28 2019-02-11 Такеда Фармасьютікал Компані Лімітед Пептидна сполука

Also Published As

Publication number Publication date
PL3242887T3 (pl) 2020-02-28
NZ748274A (en) 2022-03-25
NO2023005I1 (no) 2023-02-02
CY1122028T1 (el) 2020-10-14
IL252499A0 (en) 2017-07-31
FR23C1006I1 (fr) 2023-03-24
HRP20191614T1 (hr) 2019-12-13
TWI582109B (zh) 2017-05-11
SG11201705603YA (en) 2017-08-30
CY2023003I2 (el) 2023-06-09
CN107207576A (zh) 2017-09-26
CN112608377B (zh) 2024-02-13
HUS2300006I1 (hu) 2023-02-28
EA201791281A1 (ru) 2017-11-30
AR103242A1 (es) 2017-04-26
CY2023003I1 (el) 2023-03-24
IL281545B1 (en) 2025-05-01
ECSP17043648A (es) 2017-11-30
KR101957620B1 (ko) 2019-03-13
PH12017501252A1 (en) 2017-10-30
MY193616A (en) 2022-10-20
AU2016205435B2 (en) 2018-03-29
BR112017010596A2 (pt) 2018-03-06
NZ771547A (en) 2024-12-20
JP2019203000A (ja) 2019-11-28
CN107207576B (zh) 2020-11-24
JP2018052933A (ja) 2018-04-05
IL276492A (en) 2020-09-30
TN2017000198A1 (en) 2018-10-19
MX2021005835A (es) 2021-07-15
DK3242887T3 (da) 2019-09-02
EA201892057A1 (ru) 2019-02-28
HUE045860T2 (hu) 2020-01-28
TW201636362A (zh) 2016-10-16
WO2016111971A1 (fr) 2016-07-14
SI3242887T1 (sl) 2019-10-30
MA41315A (fr) 2017-11-15
KR20240135032A (ko) 2024-09-10
EA202090392A3 (ru) 2020-08-31
PE20170954A1 (es) 2017-07-13
EP3242887A1 (fr) 2017-11-15
LTC3242887I2 (fr) 2024-10-10
LT3242887T (lt) 2019-11-11
RS59146B1 (sr) 2019-09-30
FIC20230005I1 (fi) 2023-02-02
EA031591B1 (ru) 2019-01-31
JO3575B1 (ar) 2020-07-05
IL252499B (en) 2020-08-31
IL281545B2 (en) 2025-09-01
EA035055B1 (ru) 2020-04-22
IL276492B (en) 2021-04-29
AR131857A2 (es) 2025-05-07
EP3597662A1 (fr) 2020-01-22
KR20190026967A (ko) 2019-03-13
MX2017008927A (es) 2017-10-11
US20160199438A1 (en) 2016-07-14
NZ732000A (en) 2018-11-30
LTPA2023504I1 (fr) 2023-02-27
PT3242887T (pt) 2019-10-29
KR20230023822A (ko) 2023-02-17
MD3242887T2 (ro) 2019-11-30
MX382753B (es) 2025-03-13
UA118239C2 (uk) 2018-12-10
CA2973352A1 (fr) 2016-07-14
EA202090392A2 (ru) 2020-05-31
DOP2017000153A (es) 2017-07-15
ES2747928T3 (es) 2020-03-12
JOP20200119A1 (ar) 2017-06-16
CL2017001760A1 (es) 2018-03-16
NZ755618A (en) 2024-12-20
JP6754867B2 (ja) 2020-09-16
JP2017507124A (ja) 2017-03-16
EP3242887B1 (fr) 2019-08-14
CR20170310A (es) 2017-08-17
MA50422A (fr) 2020-08-26
NZ771043A (en) 2024-12-20
KR20170092661A (ko) 2017-08-11
ME03494B (fr) 2020-01-20
NL301217I1 (fr) 2023-02-15
AU2016205435A1 (en) 2017-06-08
SV2017005453A (es) 2018-08-27
MA41315B1 (fr) 2019-11-29
IL320236A (en) 2025-06-01
KR20210145311A (ko) 2021-12-01
JP6545766B2 (ja) 2019-07-17
KR102330764B1 (ko) 2021-11-25
US9474780B2 (en) 2016-10-25
NL301217I2 (nl) 2023-04-04
CA2973352C (fr) 2019-03-26
FR23C1006I2 (fr) 2024-01-05
JP6219534B2 (ja) 2017-10-25
IL281545A (en) 2021-05-31
ZA201703930B (en) 2019-06-26
CO2017006737A2 (es) 2017-09-29
CN112608377A (zh) 2021-04-06
PH12017501252B1 (en) 2023-06-16

Similar Documents

Publication Publication Date Title
NL301217I1 (fr)
BR112017026476A2 (fr)
BR112018003988A2 (fr)
AU2022228198B1 (fr)
BE2015C047I2 (fr)
BE2015C044I2 (fr)
BR0000763F1 (fr)
BR0000126B1 (fr)
CN303069844S (fr)
CN303069549S (fr)
CN303069471S (fr)
BR0009649B1 (fr)
CN303068337S (fr)
BR0002033B1 (fr)
BR0001810B1 (fr)
CN303068112S (fr)
CN303067986S (fr)
BR0001684B1 (fr)
BR0309344B1 (fr)
BR0309005B1 (fr)
BR0003686B1 (fr)
BR0001536B1 (fr)
BR0002402B1 (fr)
BR0003401B1 (fr)
BR0002694B1 (fr)